Cytokinetics Stock Today

CYTK -  USA Stock  

USD 43.40  1.39  3.31%

Market Performance
4 of 100
Odds Of Distress
Over 83
Cytokinetics is trading at 43.40 as of the 16th of May 2022. This is a 3.31% increase since the beginning of the trading day. The stock's last reported lowest price was 41.14. Cytokinetics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Cytokinetics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 16th of April 2022 and ending today, the 16th of May 2022. Click here to learn more.
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. The company has 84.39 M outstanding shares of which 8.75 M shares are currently shorted by private and institutional investors with about 9.49 trading days to cover. More on Cytokinetics
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Cytokinetics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Cytokinetics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Cytokinetics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Cytokinetics has very high historical volatility over the last 90 days
Cytokinetics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 21.55 M. Net Loss for the year was (228.67 M) with loss before overhead, payroll, taxes, and interest of (41.12 M).
Cytokinetics currently holds about 477.64 M in cash with (45.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.69.
Cytokinetics has a poor financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Exercise or conversion by Fady Malik of 13987 shares of Cytokinetics subject to Rule 16b-3
Cytokinetics Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Cytokinetics SEC Filings
Cytokinetics SEC Filings Security & Exchange Commission EDGAR Reports
CEORobert Blum  (View All)
Average Analyst Recommendation
Analysts covering Cytokinetics report their recommendations after researching Cytokinetics' financial statements, talking to executives and customers, or listening in on Cytokinetics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Cytokinetics. The Cytokinetics consensus assessment is calculated by taking the average forecast from all of the analysts covering Cytokinetics.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Cytokinetics based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Cytokinetics financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 4 - PoorDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares65.4 M76.9 M
Fairly Down
Increasing
Slightly volatile
Weighted Average Shares Diluted65.6 M76.9 M
Fairly Down
Increasing
Slightly volatile
Net Cash Flow from Operations(146.3 M)(142.5 M)
Fairly Down
Decreasing
Slightly volatile
Total Assets907.7 M841.3 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities644.6 M597.5 M
Significantly Up
Increasing
Slightly volatile
Current Assets578 M535.7 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities77.5 M71.9 M
Significantly Up
Increasing
Slightly volatile
Total Debt291.2 M269.9 M
Significantly Up
Increasing
Slightly volatile
Return on Average Assets(0.33)(0.306)
Significantly Down
Increasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Asset Turnover0.150.1
Way Up
Decreasing
Very volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Cytokinetics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong HoldUndervalued
Financial Strength
Cytokinetics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Cytokinetics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cytokinetics' financial leverage. It provides some insight into what part of Cytokinetics' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Cytokinetics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Cytokinetics deploys its capital and how much of that capital is borrowed.
Liquidity
Cytokinetics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 266.34 M in liabilities with Debt to Equity (D/E) ratio of 1.07, which is about average as compared to similar companies. Cytokinetics has a current ratio of 6.0, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Cytokinetics until it has trouble settling it off, either with new capital or with free cash flow. So, Cytokinetics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cytokinetics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cytokinetics to invest in growth at high rates of return. When we think about Cytokinetics' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(146.27 Million)Share
Cytokinetics (CYTK) is traded on NASDAQ Exchange in USA. It is located in 280 East Grand Avenue and employs 184 people. Cytokinetics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 3.66 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cytokinetics's market, we take the total number of its shares issued and multiply it by Cytokinetics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Cytokinetics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 84.39 M outstanding shares of which 8.75 M shares are currently shorted by private and institutional investors with about 9.49 trading days to cover. Cytokinetics currently holds about 477.64 M in cash with (45.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.69.
Check Cytokinetics Probability Of Bankruptcy
Ownership
Cytokinetics retains a total of 84.39 Million outstanding shares. The majority of Cytokinetics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Cytokinetics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Cytokinetics. Please pay attention to any change in the institutional holdings of Cytokinetics as this could imply that something significant has changed or about to change at the company. Also note that nearly thirteen million five hundred two thousand four hundred invesors are currently shorting Cytokinetics expressing very little confidence in its future performance.

Ownership Allocation (%)

Check Cytokinetics Ownership Details

Cytokinetics Stock Price Odds Analysis

What are Cytokinetics' target price odds to finish over the current price? Coming from a normal probability distribution, the odds of Cytokinetics jumping above the current price in 90 days from now is near 1%. The Cytokinetics probability density function shows the probability of Cytokinetics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Cytokinetics has a beta of 0.8984 suggesting Cytokinetics market returns are responsive to returns on the market. As the market goes up or down, Cytokinetics is expected to follow. Additionally, the company has an alpha of 0.3275, implying that it can generate a 0.33 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Down 43.4HorizonTargetOdds Up 43.4  
99.17%90 days
 43.40 
0.82%
Based on a normal probability distribution, the odds of Cytokinetics to move above the current price in 90 days from now is near 1 (This Cytokinetics probability density function shows the probability of Cytokinetics Stock to fall within a particular range of prices over 90 days) .

Cytokinetics Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Cytokinetics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cytokinetics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cytokinetics' value.
InstituionSecurity TypeTotal SharesValue
Assenagon Asset Management SaCommon Shares1.5 M54.8 M
Frontier Capital Management Co Llc 1Common Shares409.6 K15.1 M
Simplex Trading LlcCall Options22.4 K824 K
View Cytokinetics Diagnostics

Cytokinetics Historical Income Statement

Cytokinetics Income Statement is one of the three primary financial statements used for reporting Cytokinetics's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Cytokinetics revenue and expense. Cytokinetics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Cytokinetics Selling General and Administrative Expense is increasing as compared to previous years. The last year's value of Selling General and Administrative Expense was reported at 96.8 Million View More Fundamentals

Cytokinetics Stock Against Markets

Picking the right benchmark for Cytokinetics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Cytokinetics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Cytokinetics is critical whether you are bullish or bearish towards Cytokinetics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Cytokinetics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Money Flow Index Now

   

Money Flow Index

Determine momentum by analyzing Money Flow Index and other technical indicators
All  Next Launch Module

Cytokinetics Corporate Directors

Cytokinetics corporate directors refer to members of a Cytokinetics board of directors. The board of directors generally takes responsibility for the Cytokinetics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Cytokinetics' board members must vote for the resolution. The Cytokinetics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Edward Kaye - DirectorProfile
John Henderson - Independent DirectorProfile
Wendall Wierenga - Independent DirectorProfile
Santo Costa - Independent DirectorProfile

Investing Cytokinetics

You need to understand the risk of investing before taking a position in Cytokinetics. The danger of trading Cytokinetics is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Cytokinetics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Cytokinetics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Cytokinetics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Trending Equities. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.